BridgeMD
New treatment option for Multiple Myeloma Refractory
Official title Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
ClinicalTrials.gov ID: NCT07094048
What this study is testing
What is Target trough IgG level of 8-10 g/L?
Target trough IgG level of 8-10 g/L is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for multiple myeloma refractory.
Also referred to as Standard of care.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Multiple myeloma patient:
- ≥ 18 years old
- ≥ 1 prior lines of therapy
- Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
- On previous Ig support or not
You likely can't join if
- Less than 18 years old
- Pregancy or breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Québec, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Québec, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.